У нас вы можете посмотреть бесплатно LEAP-011: exploring first-line pembrolizumab + lenvatinib for advanced urothelial carcinoma или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and University of Paris-Saclay, Gif-sur-Yvette, France, outlines the results of the Phase III LEAP-011 (NCT03898180) trial investigating first-line pembrolizumab plus lenvatinib for patients with advanced urothelial carcinoma (UC) who are ineligible for platinum-based chemotherapy. Pembrolizumab is currently approved for first-line treatment of patients who are cisplatin-ineligible who have previously been treated and lenvatnaib has previously demonstrated activity in advanced tumors. Additionally, the KEYNOTE-146 (NCT02501096) trial demonstrated promising preliminary activity with this combination in patients with advanced UC. However, the LEAP-011 study found no difference in either progression-free survival (PFS) or overall survival (OS) between pembrolizumab plus Lenvatinib versus pembrolizumab monotherapy. A small difference was found in overall response rate (ORR), however, overall these results were not deemed positive. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.